- Researchers tested experimental PCAI compounds against pancreatic cancer cells carrying KRAS mutations.
- One leading compound blocked more than 90% of cancer cell migration in laboratory testing.
- The approach is promising, but it remains early stage and has not yet been tested as a treatment in people.
Pancreatic cancer remains one of the hardest cancers to treat.
One reason is KRAS.
Mutations in this gene are extremely common in pancreatic ductal adenocarcinoma and help drive tumour growth, spread and treatment resistance.
Researchers are now testing a new class of experimental compounds called PCAIs.
These were designed to interfere with abnormal signalling linked to cancer-driving G-proteins, including KRAS-related pathways.
In the new study, scientists tested PCAIs on pancreatic cancer cells carrying KRAS mutations.
Two compounds showed strong anticancer activity.
The researchers then focused on one leading compound called NSL-YHJ-2-27.
At a low concentration, it blocked more than 90% of cancer cell migration.
That matters because the ability to move and invade is central to how pancreatic cancer spreads.
The compound also disrupted the actin cytoskeleton, which gives cells their shape and helps them move.
Cancer cells became rounder and less mobile.
The most surprising finding was how the compounds affected major cancer signalling pathways.
Rather than simply switching down MAPK and PI3K/AKT signalling, they pushed these pathways into overactivation.
That may sound counterintuitive because these pathways usually help cancer cells grow.
But too much activation can destabilise the cell.
In this case, it appeared to trigger oxidative stress, caspase activity and apoptosis, which is programmed cell death.
The compounds also changed gene expression.
Some tumour-suppressing genes became more active, while genes linked to progression and metastasis became less active.
The results were also seen in 3D tumour spheroid models, which are more realistic than flat cell cultures.
That strengthens the case for further research.
- Metformin may mimic some exercise-related metabolic effects in prostate cancer care
- High intake of ultra-processed foods linked to higher death risk in cancer survivors
- Scientists uncover hidden pathways pancreatic cancer uses to spread
But the caveat is big.
This is still preclinical work.
It does not mean there is a new pancreatic cancer treatment available.
Many compounds look impressive in lab models and fail later in animals or humans.
Even so, the study is interesting because it attacks pancreatic cancer from a different angle.
Instead of delicately suppressing one pathway, it may overload the cancer cell’s own signalling machinery until it breaks.
